News for Healthier Living
Automation of Nuclear Chemistry Processes Leads to More Efficient Production of Astatine for Cancer Therapy
Astatine-211 (At-211) is a promising alpha emitting radioisotope for cancer therapy, but its short 7.2-hour half-life means that it must be handled quickly to minimize losses due to radioactive decay. In this research, scientists designed and tested an automated device for producing At-211 that improves production time and efficiency. The device also minimizes the dose of radioactivity to production staff and reduces the time needed to prepare samples for shipment.
December 20, 2024
December 21 2024December 20 2024December 19 2024December 18 2024December 17 2024December 16 2024December 15 2024December 14 2024December 13 2024December 12 2024December 11 2024December 10 2024December 9 2024December 8 2024
|
|
|
|
|